Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


AstraZeneca 'disappointed but confident' over Nexium patent decision in Europe

This article was originally published in Scrip

Executive Summary

AstraZeneca has informed Scrip that it "has confidence in its intellectual property portfolio protecting Nexium (esomeprazole)" following the decision of the European Patent Office to revoke one of its patents covering the proton pump inhibitor for oral administration (patent EP 1 020 461) following thirteen oppositions from generic drug manufacturers including Teva. However, it was "disappointed" by the ruling.


Related Companies




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts